PepGen News and Activities

PepGen is a company listed under the stock ticker PEPG (US).

View the org chart displaying its 23 main executives

Most searched biographies at PepGen

• James McArthur, Chief Executive Officer and Executive Board Member
• Habib Dable, Director
• Josh Resnick, Non-Executive Director

Popular executive movements at PepGen

• Patricia Fraser, Vice President, Pharmacovigilance, has left the company  (posted on December 9 2025).
• Joseph Vittiglio has joined the company as Chief Business and Legal Officer  (posted on December 8 2025).

Create your alert
to follow the executive moves at PepGen.

PepGen has 3,493 competitors including UnitedHealth Group (United States (USA)), Kaiser Permanente (United States (USA)) and HCA (United States (USA)).

Popular M&A news in Healthcare

• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Freeman Health System has acquired Northwest Health (posted on June 2 2026).
• Garner Health has just announced a $100 Million fundraising (posted on May 29 2026).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board at Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer at Royalty Pharma

Learn more about the Healthcare industry

Press releases by PepGen

• PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors | PepGen
• News Releases | PepGen
• PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments | PepGen
• Scientific Publications | PepGen
• PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) | PepGen
• PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society | PepGen
• PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 | PepGen
• PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences | PepGen
• PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference | PepGen
• PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments | PepGen
• View more press releases Close

Social media about PepGen

• PepGen on Wikipedia, Google News & Yahoo Finance
• PepGen on LinkedIn, X (Twitter) & YouTube